24.12.2012 Views

tailor-made solutions for scalable processes - Chemistry Today

tailor-made solutions for scalable processes - Chemistry Today

tailor-made solutions for scalable processes - Chemistry Today

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

ANDREAS MEUDT<br />

SVEN NERDINGER<br />

BERND LEHNEMANN<br />

Suzuki Coupling at Clariant:<br />

<strong>tailor</strong>-<strong>made</strong> <strong>solutions</strong> <strong>for</strong><br />

<strong>scalable</strong> <strong>processes</strong><br />

ABSTRACT<br />

Clariant, the first chemical company to develop an industrial-scale Suzuki process in the early 1990s, offers<br />

a broad portfolio of customized <strong>solutions</strong> <strong>for</strong> catalytic C-C coupling <strong>processes</strong> from gram to ton scale. This<br />

article highlights latest industrial developments in this area, with a special emphasis on the production of the<br />

required boronic acids. Latest development in this area is a new synthesis method <strong>for</strong> aliphatic boronic<br />

acids, using a newly developed hydroboration-based method. Furthermore, alternative syntheses of biaryls<br />

are discussed which sometimes are more economic than Suzuki couplings.<br />

The Suzuki coupling reaction - the transition-metal catalyzed C-C bond <strong>for</strong>mation between an<br />

organoboronic derivative and an organohalide or sulfonate - is a valuable tool <strong>for</strong> the organic chemist.<br />

It is - although still constantly being improved 1 - widely employed <strong>for</strong> construction of biaryl and heterobiaryl<br />

structures in the laboratory and - within the last ten years - has found its way into industrial manufacture of<br />

fine and specialty chemicals, too.<br />

HISTORY: THE OTBN STORY<br />

When in the early 1990s the sartanes family of angiotensin converting enzyme inhibitors emerged from the<br />

initially introduced Losartan 2 , O-tolylbenzonitrile (OTBN) was chosen as a starting material <strong>for</strong> the industrial<br />

production of one of these compounds (Scheme 1). The first syntheses being lenghty and expensive (5 steps),<br />

about ten companies tried to find a more economic production route to this biphenyl structure, among them<br />

the part of <strong>for</strong>mer Hoechst AG which is now part of Clariant’s Pharmaceutical Fine Chemical Business.<br />

They decided to investigate a C-C coupling pathway, leading to one of the first industrial-scale applications<br />

of a Suzuki protocol ten years ago.<br />

To fit the needs of a large-scale Suzuki process, it was necessary to find a catalyst system which could be<br />

easily recycled and would provide the product in high yields with high selectivity at low palladium loadings.<br />

Furthermore, the reaction conditions had to allow easy separation of the product from the reaction mixture.<br />

Clariant’s approach (shown in Scheme 1) was based on the water-soluble ligand tris(3-sulfonatophenyl)<br />

phosphine (TPPTS) which is commercially<br />

available and - when used in a biphasic<br />

reaction medium - allows <strong>for</strong> easy reuse of<br />

the aqueous phase carrying the catalyst<br />

while the product is isolated from the<br />

organic phase 3 . Several hundred tons of<br />

OTBN have been produced using this<br />

process.<br />

Scheme 1: The sartanes, their precursor OTBN and Clariant’s Suzuki approach<br />

6<br />

COUPLING OF<br />

NON-ACTIVATED AND<br />

DEACTIVATED SUBSTRATES<br />

In the meantime, Suzuki coupling has<br />

emerged as the most common tool <strong>for</strong><br />

C-C coupling in the fine chemicals area<br />

due the usually mild reaction conditions,<br />

good yields and high functional group<br />

tolerance. Although the palladium-TPPTS<br />

system is still successfully applied to many<br />

Suzuki couplings and often shows far<br />

superior reactivity compared to other<br />

early-generation catalyst systems like<br />

CHIRAL CATALYSIS - Oxidation and C-C Coupling supplement to chimica oggi • <strong>Chemistry</strong> <strong>Today</strong>


tetrakis(triphenylphosphine)palladium,<br />

especially with aryl and heteroaryl<br />

bromides, new synthetic and economic<br />

challenges involving heteroaromatic<br />

coupling partners and cheap but less<br />

reactive non-activated chloroaromatics<br />

lead to the discovery of new, highly active<br />

catalyst systems. Due to the excellent<br />

backwards integration with Clariant’s<br />

know-how in boronic acid production und<br />

aromatic halogenation, Clariant offers<br />

<strong>tailor</strong>-<strong>made</strong> <strong>solutions</strong> <strong>for</strong> all the<br />

pharmaceutical industry’s needs <strong>for</strong><br />

coupling products. For example, a highly<br />

versatile catalyst system developed by Fu<br />

and co-workers, palladium/tri-tert-butyl<br />

phosphine (Scheme 2), shows excellent<br />

results in the coupling of deactivated aryl<br />

chlorides at low catalyst loads4 and is not<br />

patent protected, thus being a system of<br />

choice <strong>for</strong> the outsourcing needs of pharmaceutical companies who do not want to depend on a single<br />

source or complicated intellectual property situations. In many cases even tricyclohexylphosphine is a<br />

sufficiently active ligand - not only <strong>for</strong> palladium, but also <strong>for</strong> nickel which can often be used as a substitute.<br />

With Clariant’s experience in organometallic chemistry, we are able to make customized phosphine ligands<br />

as well. For instance, the reaction of 2-hydroxybiphenyl with phosphorus trichloride and then with a<br />

Grignard compound leads to high yields of 2-dialkylphosphino-2’-hydroxybiphenyls5 Scheme 2: Suzuki coupling of deactivated aryl chlorides using Fu’s catalyst systems<br />

which show very high<br />

activities in challenging couplings.<br />

SUZUKI COUPLING OF HETEROAROMATIC SUBSTRATES<br />

Heteroarylphenyl and biheteroaryl derivatives are becoming more and more important as pharmaceutical<br />

building blocks, especially those involving pyridine- and furane-derived structures. Both heteroarylboronic<br />

acids and heteroaryl halides can be used to assemble these structures. With six-membered nitrogen<br />

heterocycles palladium on charcoal has<br />

been shown to be an efficient and costeffective<br />

catalyst<br />

(Scheme 3a). Although the literature states<br />

that addition of a phosphine ligand is<br />

essential <strong>for</strong> these couplings 6 , we have<br />

found a way to conduct the reaction under<br />

ligand-free conditions in high yields.<br />

This allows <strong>for</strong> easy isolation and<br />

purification of the product.<br />

Most heteroarylboronic acids and halides<br />

can be coupled under Suzuki conditions,<br />

including those derived from electron-rich<br />

heterocycles, i.e. furans and thiophenes<br />

(Scheme 3b).<br />

Additionally, Clariant has developed a<br />

copper-mediated method <strong>for</strong> the assembly<br />

of 4-arylpyridines from arylgrignard<br />

reagents and pyridines (Scheme 3c).<br />

1,4-Addition of the Grignard reagent leads<br />

to a 1,4-dihydropyridine which is easily<br />

reoxidized to the pyridine. The main<br />

advantage of this method is that normal<br />

pyridines can be used which are usually<br />

ten to fifty times cheaper than the<br />

corresponding halopyridines.<br />

C-C-COUPLING<br />

Scheme 3: Heteroaryl couplings using a) heteroaryl halides,<br />

b) heteroaryl boronic acids and c) halide-free pyridines<br />

ALIPHATIC COUPLINGS<br />

So far most alkyl boronic acids could not be coupled with satisfying yields under standard Suzuki conditions<br />

because of predominant beta-hydrogen elimination which seriously constrains the utility of the Suzuki<br />

reaction. Clariant is currently developing a process <strong>for</strong> Suzuki coupling of vinylic and especially alkyl<br />

boronic compounds 7 . Together with the new hydroboration-based pathway to functionalized alkyl and<br />

CHIRAL CATALYSIS - Oxidation and C-C Coupling supplement to chimica oggi • <strong>Chemistry</strong> <strong>Today</strong><br />

7


8<br />

C-C-COUPLING<br />

alkenylboronic acids described below, this new method provides a convenient way to assemble structures<br />

that haven’t been accessible by the Suzuki method be<strong>for</strong>e.<br />

INDUSTRIAL MANUFACTURE OF BORONIC ACIDS<br />

Most boronic acids are produced by reacting an organometallic species - usually an organolithium or a<br />

Grignard compound - with a trialkylborate, followed by aqueous workup. The organometallic species is<br />

usually <strong>for</strong>med by Grignard reaction or halogen-metal exchange using an aryl halide as starting material.<br />

But many aryl chlorides fail to undergo the Grignard reaction, and in general chlorides are not suitable <strong>for</strong><br />

halogen-metal exchange so that the<br />

expensive bromides have to be used. For<br />

this purpose Clariant has developed its<br />

lithium technology - the chloroarene<br />

precursor is metalated using solid lithium<br />

metal, and the resulting organolithium<br />

species is then reacted with a trialkyl<br />

borate (Scheme 4a). Apart from obviating<br />

the need to use expensive bromo<br />

compounds <strong>for</strong> direct metalations of<br />

haloarenes, this new methodology<br />

additionally gives rise to <strong>tailor</strong>-<strong>made</strong><br />

organolithium bases that are <strong>made</strong> in situ<br />

from chlorinated precursors and can be<br />

used <strong>for</strong> metalation of C-H acidic<br />

substrates like furanes or indoles<br />

(Scheme 4b).<br />

Aliphatic boronic acids are not as readily<br />

available as aromatic and heteroaromatic<br />

ones. Recently a broadly applicable<br />

method <strong>for</strong> the production of<br />

functionalized alkyl and alkenyl boronic<br />

acids has been devoloped by Prof. Victor<br />

Snieckus’ group in collaboration with<br />

Clariant 8 .<br />

When 2,5-dimethylhexa-2,4-diene is<br />

reacted with borane or a borane source,<br />

diisopropylprenylborane (iPP 2 BH) is<br />

<strong>for</strong>med almost exclusively. This reagent<br />

which can be generated and used in situ<br />

combines properties of both<br />

disiamylborane and allyl boranes. It can<br />

be used to hydroborate alkenes and<br />

alkynes, and the hydroboration products can be trans<strong>for</strong>med into boronic acids and esters under mild<br />

conditions (Scheme 4c). Finally these boronic ester can be either isolated or used directly <strong>for</strong> Suzuki<br />

coupling reactions.<br />

Another method currently evolving from the university laboratories is the Pd-catalyzed coupling of<br />

haloarenes with bis(pinacolato)diboron to yield boronic pinacolate esters. Using this method<br />

hydrolysis-sensitive boronic compounds can be prepared.<br />

In some cases even C-H-functionalization is possible using Rh or Ir catalysts. The main drawback of this<br />

reaction is the high price of the boron reagent and the bad atom economy of the reaction (one equivalent of<br />

boron is discarded) which precludes its use <strong>for</strong> large-scale <strong>processes</strong> (Scheme 4d).<br />

Scheme 4: Manufacture of boronic acids using Clariant’s lithium technology<br />

(a) direct metalation, b) proton abstraction by an in situ <strong>made</strong> custom base),<br />

c) diisopropylprenylborane and d) bis(pinacolato)diboron<br />

OTHER ISSUES<br />

For pharmaceutical use it is very important to achieve very low residual palladium contents in the final<br />

product. Usually these strict specifications can not be met by standard workup procedures. Even with<br />

heterogenous catalysts the amount of heavy metals leaching from the substrate is too high to be acceptable<br />

<strong>for</strong> pharmaceutical building blocks, especially in later stages of the synthesis. Apart from standard<br />

procedures like distillation, adsorption and complexation which are routinely employed to lower palladium<br />

contents 9 Clariant has developed their own proprietary technology to reach residual heavy metal contents<br />

as low as 1-2 ppm, employing readily available and cheap materials.<br />

It is often an option to use nickel instead of palladium since most of the residual nickel can be easily<br />

separated during work-up simply by proper pH adjustment, too. Besides this advantage, nickel is also<br />

traded about 50-fold cheaper than palladium and not subject to daily price changes. For activated aryl<br />

halides Pd can often be substituted by Ni. Even tosylates are amenable to nickel-catalyzed Suzuki coupling,<br />

and when no sensitive functional groups are present, Kumada coupling employing Grignard reagents<br />

CHIRAL CATALYSIS - Oxidation and C-C Coupling supplement to chimica oggi • <strong>Chemistry</strong> <strong>Today</strong>


C-C-COUPLING<br />

instead of boronic acids can be used where Ni catalysts often show superior selectivity in terms of less<br />

homocoupling-derived byproducts. At Clariant, Kumada couplings using either Pd or Ni catalysts have been<br />

per<strong>for</strong>med on a several hundred kilogram scale, too.<br />

Another important issue when it comes to industrial-scale <strong>processes</strong> are intellectual property rights.<br />

For kilo-lab and piloting campaigns <strong>for</strong> early-stage pharmaceutical intermediates whose clinical success<br />

probabality is naturally limited it is often too circumstantial to negotiate about licencing issues, and<br />

pharmaceutical companies often do not want to rely on a single source. For this reason, Clariant tries to use<br />

proprietary technologies and methods or catalysts which are available without the necessity of preliminary<br />

intellectual property agreements whenever possible to achieve a maximum of flexibility and independence<br />

from third parties <strong>for</strong> the customer.<br />

Clariant has gained experience in cross-couplings from pilot plant up to several hundred ton scale <strong>for</strong> more<br />

than ten years now, having manufactured more than 25 different carbocyclic and heterocyclic boronic acids<br />

and more than 20 different biaryls, heterobiaryls and oligophenyls on an industrial scale. Backed up by this<br />

know-how, Clariant is well prepared <strong>for</strong> future challenges: The trend towards ever increasing substrate<br />

complexity as well as heteroatom and functional group diversity at increasing economic efficiency is clearly<br />

visible.<br />

ANDREAS MEUDT*, SVEN NERDINGER<br />

BERND LEHNEMANN<br />

* Corresponding author:<br />

Clariant GmbH<br />

Industriepark Höchst, Building D569<br />

D-65926 Frankfurt - Germany<br />

REFERENCES<br />

1. <strong>for</strong> recent reviews see F. Bellina, A. Carpita, R. Rossi, Synthesis 2004,<br />

15, 2419, and references cited therein.<br />

2. R.D. Larsen, A.O. King, C.Y. Chen, E.G. Corley, B.S. Foster, F.E. Roberts,<br />

C. Yang, D.R. Lieberman, R.A. Reamer, D.M. Tschaen, T.R. Verhoeven,<br />

P.J. Reider, Y.S. Lo, L.T. Rossano, A.S. Brookes, D. Meloni, J.R. Moore,<br />

J.F. Arnett, J. Org. Chem. 1994, 59, 6391.<br />

3. S. Haber, J. Manero, EP 0694530 (Hoechst AG), 1995.<br />

4. A.F. Littke, C. Dai, G.C. Fu, J. Am. Chem. Soc. 2000, 122, 4020.<br />

5. H.-J. Kleiner, D. Regnat, EP 0748811 (Hoechst AG), 1996.<br />

6. T. Tagata, M. Nishida, J. Org. Chem. 2003, 68, 9412.<br />

7. To be published soon.<br />

8. A.V. Kalinin, S. Scherer, V. Snieckus, Angew. Chem. Int. Ed. 2003, 42,<br />

3399.<br />

9. C.E.Garrett, K. Prasad, Adv. Synth. Catal. 2004, 346, 889.<br />

CHIRAL CATALYSIS - Oxidation and C-C Coupling supplement to chimica oggi • <strong>Chemistry</strong> <strong>Today</strong>

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!